Published in Melanoma Res on October 01, 2001
Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst (2009) 0.86
Inducible hsp70 in the regulation of cancer cell survival: analysis of chaperone induction, expression and activity. Cancers (Basel) (2011) 0.83
Quercetin and ovarian cancer: An evaluation based on a systematic review. J Res Med Sci (2016) 0.78
Suppression of HSP27 increases the anti‑tumor effects of quercetin in human leukemia U937 cells. Mol Med Rep (2015) 0.75
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst (1998) 2.32
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 2.08
Hydrogen peroxide-related colitis (previously known as "pseudolipomatosis"): a series of cases occurring in an epidemic pattern. Endoscopy (2007) 2.07
AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology (2000) 2.05
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer (1991) 1.95
Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology (2005) 1.89
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol (2002) 1.82
Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol (1994) 1.79
In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother Pharmacol (2000) 1.77
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol (1989) 1.73
The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer (2000) 1.71
Brief report: disseminated mycobacteriosis caused by drug-resistant Mycobacterium triplex in a human immunodeficiency virus-infected patient during highly active antiretroviral therapy. Clin Infect Dis (2000) 1.65
From the fetal liver to spleen and gut: the highway to natural antibody. Mucosal Immunol (2009) 1.59
Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res (1997) 1.58
Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol (2000) 1.55
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 1.55
Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol (2001) 1.54
Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood (2001) 1.52
Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer (2000) 1.50
Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia (2003) 1.49
Fechtner syndrome: report of a third family and literature review. Br J Haematol (1993) 1.49
Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ (2008) 1.48
Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. J Infect Dis (1997) 1.47
Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res (1999) 1.46
Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol (2000) 1.44
Morphological, immunochemical, and biochemical study of rabbit achilles tendon at various ages. J Bone Joint Surg Am (1980) 1.43
Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res (2000) 1.35
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35
Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology (1997) 1.31
Comparative study of antibodies to native and denatured DNA. J Immunol (1970) 1.29
Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res (2001) 1.29
Experimental skin lesions in mice resembling systemic lupus erythematosus. Arthritis Rheum (1973) 1.27
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res (1984) 1.26
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res (1983) 1.25
Changes in Ia-like antigen expression on malignant human cells. Immunogenetics (1981) 1.22
Role of interleukins 1 and 2 on human thymocyte mitogen activation. Cell Immunol (1981) 1.17
Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer (2005) 1.17
Experimental renal disease induced by DNA-anti-DNA immune complexes. J Clin Invest (1972) 1.13
Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenetics (1984) 1.12
Expression of HL-A antigens in synchronized cultures of human lymphocytes. J Immunol (1972) 1.12
Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol (2002) 1.12
Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol (1998) 1.10
β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene (2012) 1.10
NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol (2006) 1.10
Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res (1986) 1.08
Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer (2000) 1.08
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer (2006) 1.08
Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin. Hum Immunol (1996) 1.06
Regeneration of rabbit calcaneal tendon: a morphological and immunochemical study. Cell Tissue Res (1978) 1.06
Evidence that hydrogen sulphide can modulate hypothalamo-pituitary-adrenal axis function: in vitro and in vivo studies in the rat. J Neuroendocrinol (2000) 1.05
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol (2009) 1.03
Immune complex nephritis in Schistosoma mansoni-infected mice. Eur J Immunol (1976) 1.03
Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol (1999) 1.03
Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest (1996) 1.03
The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res (2002) 1.02
Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J Natl Cancer Inst (1981) 1.02
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS (2001) 1.02
Significance of epidermal growth factor receptor expression in primary human endometrial cancer. Int J Cancer (1994) 1.02
Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene (1995) 1.02
A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst (1982) 1.02
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. Br J Cancer (2012) 1.01
Aortic antioxidant defence mechanisms: time-related changes in cholesterol-fed rabbits. Atherosclerosis (1990) 1.00
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene (2011) 0.99
Distribution of laminin and collagen type-IV in benign and malignant lesions of melanocytic origin. Int J Cancer (1985) 0.99
Human thymoma: immunologic characteristics of the lymphocytic component. Cancer (1981) 0.99
Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood (2001) 0.99
Growth-inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary colorectal tumors. Int J Cancer (1992) 0.99
Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. J Pathol (1995) 0.98
Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemother Pharmacol (1991) 0.98
Immunochemical localization of contractile proteins in mammalian meiotic chromosomes. Cell Tissue Res (1980) 0.98
Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst (1984) 0.97
Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol (1983) 0.97
Dietary alpha-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells. J Lipid Res (2003) 0.97
HLA-C heavy chains free of beta2-microglobulin: distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon-gamma responsiveness. Tissue Antigens (1997) 0.97
A primary amelanotic melanoma of the vagina diagnosed by immunocytochemistry. Int J Gynaecol Obstet (1989) 0.97
Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol (1997) 0.96
Type II estrogen receptors in the papillary cystic tumor of the pancreas. Am J Clin Pathol (1989) 0.96
Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. Br J Haematol (1995) 0.96
Prognostic significance of the Ca(2+) binding protein S100A2 in laryngeal squamous-cell carcinoma. Int J Cancer (2000) 0.96
Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res (2001) 0.95
Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer (1995) 0.95
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer (1999) 0.95
Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol (1995) 0.94
Telomerase in brain tumors. Childs Nerv Syst (2002) 0.94